US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Aspire Biopharma Holdings Inc.

0.9133

+0.00330.36%

Post-market: 0.8821-0.0312-3.42%19:56 EDT

Volume:172.79K

Turnover:152.70K

Market Cap:4.59M

PE:-0.01

High:0.9380

Open:0.9019

Low:0.8200

Close:0.9100

52wk High:35.01

52wk Low:0.5483

Shares:5.02M

Float Shares:3.07M

Volume Ratio:0.10

T/O Rate:5.64%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-65.9600

EPS(LYR):-0.1190

ROE:--

ROA:-195.11%

PB:-0.40

PE(LYR):-7.67

Loading ...

Overview Company News Filings

Aspire Biopharma Holdings Inc trading halted, news pending

Aspire Biopharma Announces 1-for-40 Reverse Stock Split

Aspire Biopharma Director Surendra Ajjarapu Resigns

Aspire Biopharma Advances High-Dose Sublingual Aspirin to FDA-Supported Clinical Trial

Aspire Biopharma Swaps $1.75 Million Debt for Common Stock

Aspire Biopharma Transfers Listing to Nasdaq Capital Market After Extension Granted

Aspire Biopharma Reports Q3 2025 Update and Advances Sublingual Drug Delivery Programs

BRIEF-Aspire Biopharma Holdings Files For Offering Of Up To 41.5 Million Shares By Selling Shareholder - SEC Filing

Aspire Biopharma Holdings Inc Files for Offering of up to 41.5 Mln Shares by Selling Shareholder - SEC Filing

THOMSON REUTERS

Aspire Biopharma Submits Pre-IND Meeting Request to FDA for Sublingual Aspirin Product

Aspire Biopharma Holdings Adds Dr. Mark J. Jaroszeski to Scientific Team

Aspire Biopharma Holdings Inc. Files Amendment to 10-Q Quarterly Report

Aspire Biopharma Hldgs Q3 EPS $(0.04) Down From $(0.01) YoY, Sales $1.941K

Aspire Biopharma Holdings Inc - on Nov 11, Entered Eloc Agreement With Arena Business Solutions - SEC Filing

THOMSON REUTERS

Aspire Biopharma Holdings - Under Eloc Agreement, Co Has Right but Not Obligation to Direct Arena to Purchase up to $100 Mln of Co’s Stock

THOMSON REUTERS

Aspire Biopharma Announces $100 Million Unregistered Share Sale Under Equity Line Agreement

Aspire Biopharma Holdings Inc. held special shareholder meeting

Aspire Biopharma Faces Nasdaq Delisting After Compliance Failures

Aspire Biopharma Holdings Announces Breakthrough in Sublingual Drug Delivery with New Patent Application

Aspire Biopharma Holdings Inc. to Present Pipeline Updates at Noble Capital Markets Emerging Growth Virtual Equity Conference

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ASBP/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ASBP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ASBP\",,,,,undefined,":{"symbol":"ASBP","market":"US","secType":"STK","nameCN":"Aspire Biopharma Holdings Inc.","latestPrice":0.9133,"timestamp":1774641600000,"preClose":0.91,"halted":0,"volume":172794,"hourTrading":{"tag":"盘后","latestPrice":0.8821,"preClose":0.9133,"latestTime":"19:56 EDT","volume":2047,"amount":1770.841585,"timestamp":1774655819972,"change":-0.0312,"changeRate":-0.034162,"amplitude":0.079601},"delay":0,"changeRate":0.0036263736263735928,"floatShares":3066100,"shares":5024142,"eps":-65.96,"marketStatus":"Market Closed","change":0.0033,"latestTime":"03-27 16:00:00 EDT","open":0.9019,"high":0.938,"low":0.82,"amount":152702.46404700002,"amplitude":0.12967,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-65.96,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":0.91,"preHourTrading":{"tag":"盘前","latestPrice":0.9298,"preClose":0.91,"latestTime":"09:18 EDT","volume":3643,"amount":3223.6983503,"timestamp":1774617485599,"change":0.0198,"changeRate":0.021758,"amplitude":0.10022},"postHourTrading":{"tag":"盘后","latestPrice":0.8821,"preClose":0.9133,"latestTime":"19:56 EDT","volume":2047,"amount":1770.841585,"timestamp":1774655819972,"change":-0.0312,"changeRate":-0.034162,"amplitude":0.079601},"volumeRatio":0.097551},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ASBP\",,,,,undefined,":{"symbol":"ASBP","floatShares":3066100,"roa":"-195.11%","roe":"--","lyrEps":-0.11904,"volumeRatio":0.097551,"shares":5024142,"dividePrice":0,"high":0.938,"amplitude":0.12967,"preClose":0.91,"low":0.82,"week52Low":0.5483,"pbRate":"-0.40","psRate":"2364.01","week52High":35.012,"institutionHeld":0,"latestPrice":0.9133,"eps":-65.96,"divideRate":0,"volume":172794,"delay":0,"ttmEps":-65.96,"open":0.9019,"prevYearClose":5.276,"prevWeekClose":0.7181,"prevMonthClose":1.39,"prevQuarterClose":5.276,"fiveDayClose":0.7181,"twentyDayClose":1.39,"sixtyDayClose":5.68},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ASBP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-01-16","symbol":"ASBP","defaultRemindTime":1768573800000,"type":"split","dateTimestamp":1768539600000,"forFactor":40,"toFactor":1,"ratio":40}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ASBP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ASBP\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ASBP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ASBP","date":"2026-03-26","current":-0.013846,"percent":0.880597,"low":-107.647863,"twenty":-4.677726,"median":-0.926003,"eighty":-0.359587,"high":-0.160836,"avg":-8.772872,"sd":17.389974,"marketCap":5677280},"quantilePoints":[{"date":"2025-03-07","current":-61.718107,"twenty":-79.515888,"median":-61.718107,"eighty":-58.474317,"marketCap":40003023},{"date":"2025-03-14","current":-41.62384,"twenty":-63.871064,"median":-57.344015,"eighty":-54.828644,"marketCap":26978783},{"date":"2025-03-21","current":-49.388839,"twenty":-61.718107,"median":-55.259235,"eighty":-45.464716,"marketCap":32011722},{"date":"2025-03-28","current":-47.36506,"twenty":-59.766092,"median":-48.376949,"eighty":-45.613987,"marketCap":30699995},{"date":"2025-04-04","current":-38.75323,"twenty":-56.183571,"median":-46.367595,"eighty":-43.647619,"marketCap":25118177},{"date":"2025-04-11","current":-38.035578,"twenty":-55.34679,"median":-45.929755,"eighty":-40.946376,"marketCap":24653026},{"date":"2025-04-17","current":-39.57853,"twenty":-55.287942,"median":-45.474044,"eighty":-39.546954,"marketCap":25653101},{"date":"2025-04-25","current":-36.428037,"twenty":-53.967461,"median":-44.487272,"eighty":-38.006872,"marketCap":23611087},{"date":"2025-05-02","current":-25.763721,"twenty":-50.875815,"median":-42.879731,"eighty":-36.06634,"marketCap":16698936},{"date":"2025-05-09","current":-24.070062,"twenty":-48.174572,"median":-41.62384,"eighty":-32.456117,"marketCap":15601179},{"date":"2025-05-16","current":-8.64997,"twenty":-47.360753,"median":-40.170558,"eighty":-27.896584,"marketCap":11330354},{"date":"2025-05-23","current":-0.643502,"twenty":-46.76371,"median":-38.75323,"eighty":-25.110657,"marketCap":10952545},{"date":"2025-05-30","current":-1.730761,"twenty":-46.192459,"median":-37.963813,"eighty":-23.557658,"marketCap":29457944},{"date":"2025-06-06","current":-0.976857,"twenty":-45.929755,"median":-36.514155,"eighty":-4.677726,"marketCap":16626329},{"date":"2025-06-13","current":-1.091781,"twenty":-45.929755,"median":-34.956848,"eighty":-1.13913,"marketCap":18582368},{"date":"2025-06-20","current":-0.913361,"twenty":-45.88526,"median":-32.509654,"eighty":-1.103849,"marketCap":15545618},{"date":"2025-06-27","current":-0.879171,"twenty":-45.613987,"median":-30.966702,"eighty":-1.056614,"marketCap":14963696},{"date":"2025-07-03","current":-0.838948,"twenty":-45.240807,"median":-27.672677,"eighty":-0.926003,"marketCap":14279083},{"date":"2025-07-11","current":-0.994957,"twenty":-44.49445,"median":-25.763721,"eighty":-0.89957,"marketCap":16934405},{"date":"2025-07-18","current":-1.022827,"twenty":-44.487272,"median":-24.235121,"eighty":-0.913361,"marketCap":17408745},{"date":"2025-07-25","current":-1.492005,"twenty":-43.705031,"median":-23.47441,"eighty":-0.913361,"marketCap":25394273},{"date":"2025-08-01","current":-1.094942,"twenty":-43.417971,"median":-12.855253,"eighty":-0.926003,"marketCap":18636159},{"date":"2025-08-08","current":-0.957894,"twenty":-42.341491,"median":-1.730761,"eighty":-0.926003,"marketCap":16303583},{"date":"2025-08-15","current":-1.119076,"twenty":-41.810429,"median":-1.408829,"eighty":-0.936633,"marketCap":19046927},{"date":"2025-08-22","current":-1.407348,"twenty":-41.62384,"median":-1.381965,"eighty":-0.948126,"marketCap":26605351},{"date":"2025-08-29","current":-1.458172,"twenty":-41.494663,"median":-1.401585,"eighty":-0.950712,"marketCap":27566154},{"date":"2025-09-05","current":-1.427258,"twenty":-40.909001,"median":-1.428961,"eighty":-0.956458,"marketCap":26981748},{"date":"2025-09-12","current":-1.182832,"twenty":-39.815341,"median":-1.395821,"eighty":-0.96387,"marketCap":22360975},{"date":"2025-09-19","current":-1.153491,"twenty":-39.515377,"median":-1.375367,"eighty":-0.974558,"marketCap":21806284},{"date":"2025-09-26","current":-0.990278,"twenty":-38.902502,"median":-1.341067,"eighty":-0.987594,"marketCap":18720816},{"date":"2025-10-03","current":-1.100309,"twenty":-38.179108,"median":-1.232741,"eighty":-0.956458,"marketCap":20800907},{"date":"2025-10-10","current":-0.881819,"twenty":-37.978166,"median":-1.192915,"eighty":-0.950195,"marketCap":16670441},{"date":"2025-10-17","current":-0.836759,"twenty":-37.504515,"median":-1.176427,"eighty":-0.934507,"marketCap":15818594},{"date":"2025-10-24","current":-0.880247,"twenty":-36.758157,"median":-1.164494,"eighty":-0.913361,"marketCap":16640725},{"date":"2025-10-31","current":-0.986087,"twenty":-36.462484,"median":-1.14993,"eighty":-0.912711,"marketCap":18641575},{"date":"2025-11-07","current":-0.694243,"twenty":-35.704643,"median":-1.134878,"eighty":-0.909799,"marketCap":13124382},{"date":"2025-11-14","current":-0.275601,"twenty":-35.070237,"median":-1.124309,"eighty":-0.898954,"marketCap":5210132},{"date":"2025-11-21","current":-0.235902,"twenty":-33.9751,"median":-1.119076,"eighty":-0.881505,"marketCap":4838687},{"date":"2025-11-28","current":-0.553115,"twenty":-32.997658,"median":-1.106147,"eighty":-0.854611,"marketCap":11360337},{"date":"2025-12-05","current":-0.481425,"twenty":-32.429349,"median":-1.100309,"eighty":-0.832214,"marketCap":9887900},{"date":"2025-12-12","current":-0.546836,"twenty":-31.853289,"median":-1.093218,"eighty":-0.820326,"marketCap":11231365},{"date":"2025-12-19","current":-0.524858,"twenty":-30.859054,"median":-1.081231,"eighty":-0.778555,"marketCap":10779960},{"date":"2025-12-26","current":-0.507589,"twenty":-29.773963,"median":-1.072669,"eighty":-0.702707,"marketCap":10425286},{"date":"2026-01-02","current":-0.690217,"twenty":-28.344399,"median":-1.050409,"eighty":-0.690255,"marketCap":14176239},{"date":"2026-01-09","current":-0.540556,"twenty":-26.497162,"median":-1.035468,"eighty":-0.662273,"marketCap":11102392},{"date":"2026-01-16","current":-0.271586,"twenty":-26.171348,"median":-1.031821,"eighty":-0.631908,"marketCap":5578064},{"date":"2026-01-23","current":-0.236788,"twenty":-25.763721,"median":-1.0257,"eighty":-0.565151,"marketCap":4863341},{"date":"2026-01-30","current":-0.191,"twenty":-25.584308,"median":-1.01392,"eighty":-0.553115,"marketCap":3922916},{"date":"2026-02-06","current":-0.172685,"twenty":-24.400181,"median":-1.00377,"eighty":-0.544219,"marketCap":3546746},{"date":"2026-02-13","current":-0.171377,"twenty":-24.070062,"median":-0.994957,"eighty":-0.524858,"marketCap":3519876},{"date":"2026-02-20","current":-0.359587,"twenty":-23.760036,"median":-0.986087,"eighty":-0.515752,"marketCap":7385488},{"date":"2026-02-27","current":-0.354694,"twenty":-23.516034,"median":-0.961629,"eighty":-0.507589,"marketCap":7285005},{"date":"2026-03-06","current":-0.320448,"twenty":-23.365326,"median":-0.950712,"eighty":-0.493983,"marketCap":6581626},{"date":"2026-03-13","current":-0.275194,"twenty":-18.316039,"median":-0.944432,"eighty":-0.472111,"marketCap":5652159},{"date":"2026-03-20","current":-0.160836,"twenty":-10.332083,"median":-0.936633,"eighty":-0.400965,"marketCap":3303373},{"date":"2026-03-26","current":-0.276417,"twenty":-4.677726,"median":-0.926003,"eighty":-0.359587,"marketCap":5677280}],"updateTime":1774654417503},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ASBP\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2603937660","title":"Aspire Biopharma Holdings Inc trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2603937660","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603937660?lang=en_us&edition=fundamental","pubTime":"2026-01-16 08:50","pubTimestamp":1768524610,"startTime":"0","endTime":"0","summary":"19:50 EST Aspire Biopharma (ASBP) Holdings Inc trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-m...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aspire-biopharma-holdings-inc-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aspire-biopharma-holdings-inc-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2603616141","title":"Aspire Biopharma Announces 1-for-40 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2603616141","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603616141?lang=en_us&edition=fundamental","pubTime":"2026-01-14 21:05","pubTimestamp":1768395930,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. has announced a 1-for-40 reverse stock split of its common stock, effective January 16, 2026. The company's shares will begin trading on a split-adjusted basis under the same Nasdaq ticker symbol, ASBP, with a new CUSIP number 738920 206.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire  on January 14, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDL8Mt6T6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2603658178","title":"Aspire Biopharma Director Surendra Ajjarapu Resigns","url":"https://stock-news.laohu8.com/highlight/detail?id=2603658178","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603658178?lang=en_us&edition=fundamental","pubTime":"2026-01-14 05:31","pubTimestamp":1768339873,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. announced that Surendra Ajjarapu has resigned from his position as Director, effective immediately. The company stated that his departure was not due to any disagreement with the board or management.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 13, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDLFmrw7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2601803153","title":"Aspire Biopharma Advances High-Dose Sublingual Aspirin to FDA-Supported Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2601803153","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601803153?lang=en_us&edition=fundamental","pubTime":"2026-01-07 21:01","pubTimestamp":1767790864,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. has announced a successful Type B pre-Investigational New Drug  meeting with the U.S. Food and Drug Administration  regarding its investigational product, acetylsalicylic acid 162 mg sublingual powder , intended for the emergency treatment of suspected acute myocardial infarction. The FDA provided feedback supporting a 505 regulatory filing targeted for the second half of 2026 and indicated that no additional studies are required beyond the currently planned 32-subject clinical trial. Initial evaluations of OTASA have indicated that the product was safe and well-tolerated with no reported adverse events. Results from the planned clinical trial have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL6Yfqgl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2601890949","title":"Aspire Biopharma Swaps $1.75 Million Debt for Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2601890949","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601890949?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:36","pubTimestamp":1767706574,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. has entered into Exchange Agreements with certain holders of its debt to convert approximately $1.75 million in outstanding debt into shares of the company's common stock. The debt originated from agreements made by the company's predecessor, PowerUp Acquisition Corp., in early 2024. The transaction involves accredited investors and relies on exemptions from registration under the Securities Act. Additionally, the agreements provide that, upon future financings exceeding $3 million, holders may elect to receive a portion of the proceeds in cash to repay outstanding balances.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this n","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL1bBwv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2591268463","title":"Aspire Biopharma Transfers Listing to Nasdaq Capital Market After Extension Granted","url":"https://stock-news.laohu8.com/highlight/detail?id=2591268463","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591268463?lang=en_us&edition=fundamental","pubTime":"2025-12-13 06:00","pubTimestamp":1765576828,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. announced it will transfer the listing of its common stock from the Nasdaq Global Select Market to the Nasdaq Capital Market, effective at the opening of business on December 15, 2025. The company's shares will continue to trade under the symbol \"ASBP,\" and trading will remain unaffected by the transfer. Aspire has been granted an extension by the Nasdaq Hearings Panel to meet certain conditions related to its continued listing, with key deadlines set for early 2026. The company is taking steps to address these requirements and aims to position itself for long-term shareholder value.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to genera","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL2GN9K8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2588887475","title":"Aspire Biopharma Reports Q3 2025 Update and Advances Sublingual Drug Delivery Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2588887475","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588887475?lang=en_us&edition=fundamental","pubTime":"2025-12-04 22:00","pubTimestamp":1764856818,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc.  provided a business update for the quarter ended September 30, 2025. During the third quarter, the company expanded its scientific team with the addition of Dr. Mark J. Jaroszeski, a tenured professor from the University of South Florida, to support development of its sublingual drug delivery technology. Aspire reported progress on its sublingual ED medication program, with plans to finalize formulation and manufacture a test product in the first half of 2026, and to begin a Phase 1 pharmacokinetic clinical cross-over study by mid-2026. The company highlighted the clinical validation of its technology with sublingual aspirin and noted a targeted New Drug Application  submission for this product in the first half of 2026. Aspire also pointed to continued commercial execution with Buzz Bomb Caffeine Company's second production order of two million servings of BUZZ BOMB. In addition, Aspire filed an omnibus patent application with the U.S. Patent and Tradem","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL1zvN4v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2588466450","title":"BRIEF-Aspire Biopharma Holdings Files For Offering Of Up To 41.5 Million Shares By Selling Shareholder - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2588466450","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588466450?lang=en_us&edition=fundamental","pubTime":"2025-12-03 20:49","pubTimestamp":1764766158,"startTime":"0","endTime":"0","summary":"BRIEF-Aspire Biopharma Holdings Files For Offering Of Up To 41.5 Million Shares By Selling Shareholder - SEC FilingDec 3  - Aspire Biopharma Holdings Inc ASBP.O:ASPIRE BIOPHARMA HOLDINGS INC FILES FOR OFFERING OF UP TO 41.5 MILLION SHARES BY SELLING SHAREHOLDER - SEC FILINGSource text: [ID:n0001493152-25-025819]Further company coverage: ASBP.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nFWN3X817I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2588010011","title":"Aspire Biopharma Holdings Inc Files for Offering of up to 41.5 Mln Shares by Selling Shareholder - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2588010011","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588010011?lang=en_us&edition=fundamental","pubTime":"2025-12-03 19:05","pubTimestamp":1764759952,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nFWN3X817I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2588056295","title":"Aspire Biopharma Submits Pre-IND Meeting Request to FDA for Sublingual Aspirin Product","url":"https://stock-news.laohu8.com/highlight/detail?id=2588056295","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588056295?lang=en_us&edition=fundamental","pubTime":"2025-12-02 22:00","pubTimestamp":1764684026,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. has submitted a Pre-IND meeting request and briefing package to the U.S. Food and Drug Administration  for its lead product candidate, a fast-acting, high-dose sublingual aspirin formulation intended for the treatment of suspected acute myocardial infarction . This submission marks an important step in seeking FDA guidance on the clinical development strategy and confirmation of the proposed 505 regulatory pathway. No grant or funding involving Aspire or multiple organizations is mentioned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire  on December 02, 2025, and is solely responsible for the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL7LMyND:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2586250219","title":"Aspire Biopharma Holdings Adds Dr. Mark J. Jaroszeski to Scientific Team","url":"https://stock-news.laohu8.com/highlight/detail?id=2586250219","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586250219?lang=en_us&edition=fundamental","pubTime":"2025-11-26 22:00","pubTimestamp":1764165631,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. has announced the addition of Dr. Mark J. Jaroszeski to its scientific team. Dr. Jaroszeski joins as a new member and is a tenured professor in the Department of Medical Engineering at the University of South Florida.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire  on November 26, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL2Tg3sp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2583682056","title":"Aspire Biopharma Holdings Inc. Files Amendment to 10-Q Quarterly Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2583682056","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583682056?lang=en_us&edition=fundamental","pubTime":"2025-11-15 06:03","pubTimestamp":1763157810,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. has filed an amendment to its 10-Q quarterly report for the financial quarter ended September 30, 2025. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 14, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL6KQBSQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2583502812","title":"Aspire Biopharma Hldgs Q3 EPS $(0.04) Down From $(0.01) YoY, Sales $1.941K","url":"https://stock-news.laohu8.com/highlight/detail?id=2583502812","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583502812?lang=en_us&edition=fundamental","pubTime":"2025-11-14 22:31","pubTimestamp":1763130681,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Hldgs (NASDAQ:ASBP) reported quarterly losses of $(0.04) per share. This is a 300 percent decrease over losses of $(0.01) per share from the same period last year.  The company reported $1.941 thousand","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48864104/aspire-biopharma-hldgs-q3-eps-0-04-down-from-0-01-yoy-sales-1-941k","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP","QLD","MNQmain","NQmain","SQQQ","QID","USJW.SI","PSQ","TSYW.SI","USAW.SI",".IXIC","NVIW.SI","TQQQ","BK4007"],"gpt_icon":0},{"id":"2583850612","title":"Aspire Biopharma Holdings Inc - on Nov 11, Entered Eloc Agreement With Arena Business Solutions - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2583850612","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583850612?lang=en_us&edition=fundamental","pubTime":"2025-11-14 21:02","pubTimestamp":1763125342,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nFWN3WQ113:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2583506430","title":"Aspire Biopharma Holdings - Under Eloc Agreement, Co Has Right but Not Obligation to Direct Arena to Purchase up to $100 Mln of Co’s Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2583506430","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583506430?lang=en_us&edition=fundamental","pubTime":"2025-11-14 21:02","pubTimestamp":1763125342,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nFWN3WQ113:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2583506193","title":"Aspire Biopharma Announces $100 Million Unregistered Share Sale Under Equity Line Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2583506193","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583506193?lang=en_us&edition=fundamental","pubTime":"2025-11-14 21:01","pubTimestamp":1763125301,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. has entered into an Equity Line of Credit  Agreement with Arena Business Solutions Global SPC II, Ltd., allowing the company to sell up to $100 million in common stock to Arena over a period of up to 36 months. The shares will be issued in reliance on exemptions from registration under Section 4 of the Securities Act and Regulation D, as Arena is considered an accredited investor. The sale of these unregistered shares is subject to certain terms, including the effectiveness of a registration statement for the resale of the shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gath","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL3GZlhh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2581623700","title":"Aspire Biopharma Holdings Inc. held special shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2581623700","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581623700?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:51","pubTimestamp":1762379482,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. held a special meeting of stockholders on November 4, 2025. At the meeting, stockholders approved granting the board discretionary authority to amend the certificate of incorporation to implement a reverse stock split at a ratio ranging from one-for-five to one-for-forty, to be determined at the board's discretion and effected within one year. Stockholders also approved the issuance of more than 19.99% of the outstanding shares of common stock upon exercise of certain convertible promissory notes, as well as the floor price at which the notes may be converted.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via E","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL20XJKS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2576064128","title":"Aspire Biopharma Faces Nasdaq Delisting After Compliance Failures","url":"https://stock-news.laohu8.com/highlight/detail?id=2576064128","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576064128?lang=en_us&edition=fundamental","pubTime":"2025-10-18 05:16","pubTimestamp":1760735780,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. has announced that it received a notice from the Nasdaq Stock Market LLC regarding its failure to comply with two key listing requirements: the minimum Market Value of Listed Securities  of $50 million and the minimum bid price rule. The company did not regain compliance within the designated 180-day period, leading Nasdaq staff to notify Aspire that its securities are subject to delisting. Aspire has requested a hearing before the Nasdaq Hearings Panel, which temporarily stays the suspension of its common stock and warrants. The company will present its plan to regain compliance and seek an extension, but there is no assurance that continued listing will be granted or that compliance will be achieved in the allotted time.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251017:nNDL2WX1n6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2573672268","title":"Aspire Biopharma Holdings Announces Breakthrough in Sublingual Drug Delivery with New Patent Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2573672268","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573672268?lang=en_us&edition=fundamental","pubTime":"2025-10-06 20:30","pubTimestamp":1759753832,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. has announced the filing of an omnibus patent application with the U.S. Patent and Trademark Office for its innovative sublingual drug delivery platform. The proprietary technology, which has not yet been presented at scientific conferences, is designed to enhance the pharmacokinetic performance of active pharmaceutical ingredients  by enabling rapid absorption through sublingual blood vessels. Key features of the platform include faster onset of action, reduced drug-food and drug-drug interactions, lower risk of gastrointestinal irritation, and ease of administration, particularly in emergency situations. Aspire believes this advancement could significantly improve the efficacy and safety of a wide range of medications.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and shoul","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nNDL2CxrC9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2572686796","title":"Aspire Biopharma Holdings Inc. to Present Pipeline Updates at Noble Capital Markets Emerging Growth Virtual Equity Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2572686796","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572686796?lang=en_us&edition=fundamental","pubTime":"2025-10-03 23:30","pubTimestamp":1759505417,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. to Present Pipeline Updates at Noble Capital Markets Emerging Growth Virtual Equity Conference. Aspire Biopharma Holdings Inc. will participate in the Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference on October 8-9, 2025. The company will present updates on its disruptive sublingual drug delivery technology, including its lead programs targeting FDA submission for sublingual high-dose aspirin and a sublingual ED medication in the second half of 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire  on October 03, 2025, and is solely responsible for the information contained","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251003:nNDL1ylrTt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":44,"code":"91000000","status":"200"}]}}